Form 10-K Vincerx Pharma, Inc. For: Dec 31

Related Keywords

Brazil ,China ,Palo Alto ,California ,United States ,Delaware ,India ,Washington ,Argentina ,State Of Delaware ,Germany ,East Brunswick ,New Jersey ,Oregon ,United Kingdom ,Ukraine ,Japan ,Russia ,Mexico ,Israel ,Russian ,America ,German ,American ,Alexandera Seelenberger ,Ahmedm Hamdy ,Laurai Bushnell ,Brianj Druker ,Bayer Aktiengesellschaft ,Ruthe Stevens ,Vincera Pharma ,Eli Lilly ,Acerta Pharma Calquence ,Legumain Linker ,Raquele Izumi ,Johnc Byrd ,Vincerx Pharma ,Ndas Blas ,Monte Carlo ,Vincerx Pharma Gmb ,Franciscod Salva ,Department Of Internal Medicine ,Bristol Myers Squibb Company ,Genentech United States Inc ,Genentech Inc ,Company Level ,Trademark Office ,American Association For Cancer Research ,Lifesci Acquisition Corp ,Vincerx Pharma Inc ,Lifesci Acquisition Merger Sub Inc ,Health Insurance Portability ,Cyclacel Pharmaceuticals Inc ,Human Services ,Company Certificate Of Incorporation ,Roche Holding ,Seagen Inc ,Kronos Bio Inc ,Research To Accelerate Cures ,Bayer Ag ,Janssen Pharmaceuticals ,Trust Company ,Klus Pharma Inc ,Vincera Pharma Inc ,Scientific Advisory Committee ,Duality Biologics Co ,Acerta Pharma ,Drug Administration ,Nasdaq ,Prelude Therapeutics Inc ,Public Health Service ,Advisory Committee ,Mersana Therapeutics Inc ,Delaware Supreme Court ,Public Company ,Radiological Health Office Of In Vitro Diagnostics ,Amgen Inc ,Innovent Biologics Inc ,University Of Cincinnati ,Development Expense ,Clinical Development ,Lifesci Holdings ,Office Of Inspector ,Gilead Sciences Inc ,Board Of Directors The Company ,Regulatory Agency ,National Institute Of Standards ,Growth Company Status ,European Hematology Association ,Legochem Biosciences Inc ,Company Employee Stock Purchase Program ,Co Inc ,Iksuda Therapeutics Ltd ,Immunogen Inc ,Rosedale Park ,Pediatric Research Equity ,Nasdaq Capital Market Of The Company ,Chardan Capital Markets ,American Society Of Hematology ,Macrogenics Inc ,Health Care ,Unitary Patent Court ,Astellas Pharma Inc ,Astrazeneca ,Good Laboratory Practices ,Daiichi Sankyo Company ,Medicaid Services ,Novartis International ,Johnson Inc ,Profoundbio Inc ,Centers For Medicare ,Radiological Health ,Abbvie Inc ,National Institutes Of Health ,Oregon Health ,European Union ,Securities Exchange ,Cytomx Therapeutics Inc ,Vincerx Pharma Australia Pty ,Daiichi Sankyo Inc ,Public Company Accounting Oversight Board United ,Takeda Pharmaceutical Company ,Immunomedics Inc ,Nasdaq Stock Market ,Exchange Commission ,Incorporation Or Organization ,Growth Company ,Pfizer Inc ,Us Department Of Health ,Life Sciences Group Inc ,Public Company Accounting Oversight Board ,Sumitomo Dainippon Pharma Co Ltd ,Mark One ,Its Charter ,Zip Code ,Securities Exchange Act ,Interactive Data File ,Sarbanes Oxley Act ,Exchange Act ,Nasdaq Capital Market ,United States Securities ,Annual Report ,Bayer License Agreement ,Inflation Reduction Act ,Quarterly Reports ,Current Reports ,Business Combination ,Patient Protection ,Affordable Care Act ,Education Reconciliation ,License Agreement ,Legacy Vincera Pharma ,Bayer Intellectual Property ,Biologics Price Competition ,Innovation Act ,Good Manufacturing ,Legacy Holders ,Federal Food ,Jumpstart Our Business Startups Act ,Vincera Pharma Common ,Merger Sub ,Merger Agreement ,Lifesci Acquisition Merger Sub ,Securities Act ,United States Patent ,Warrant Agreement ,Continental Stock Transfer ,Vincerx Wings ,Sci Acquisition Corp ,Legacy Vincera Pharma Common Stock ,Dissenting Shares ,Earnout Shares ,Trading Period ,Closing Price Per Share ,Closing Price Per ,Incentive Plan ,Elastase Linker ,Spindle Protein Inhibitor ,American Society ,American Association ,Cancer Research ,Daiichi Sankyo ,Genentech United States ,Gilead Sciences ,Drug Conjugate ,Hematology Association ,Annual Meeting ,Vivo Model Achieved Durable Complete Regressions ,National Institutes ,Bicycle Therapeutics ,Cytomx Therapeutics ,Duality Biologics ,Innovent Biologics ,Klus Pharma ,Legochem Biosciences ,Kronos Bio ,Sciences Group ,Approval Process ,Public Health Service Act ,Institutional Review Board ,Project Optimus ,Complete Response Letter ,Risk Evaluation ,Mitigation Strategy ,Pediatric Research Equity Act ,Accelerate Cures ,Children Act ,Preview Programs ,Orphan Drug Act ,Dear Healthcare Provider ,Reference Product Exclusivity ,Care Act ,Compliance Requirements ,Inspector General ,Social Security Act ,Reduction Act ,Companion Diagnostics ,Drug Evaluation ,Radiological Health Office ,Vitro Diagnostics ,Quality System Regulation ,Foreign Corrupt Practices Act ,Occupational Safety ,Health Act ,Resource Conservancy ,Recovery Act ,Toxic Substances Control Act ,Bayer License ,Patent Cooperation Treaty ,Versaptx Platform ,Internal Medicine ,Chief Medical Officer ,Science University ,Knight Cancer Institute School ,Summer Hours ,Memorial Day ,Labor Day ,Pharma Gmbh ,Investor Relations ,Product Candidates ,Financial Position ,Additional Capital ,Accounting Standards Update ,Going Concern ,Regulatory Approval ,Trials Regulation ,Foreign Corrupt Practices ,Third Parties ,Intellectual Property ,Drug Price Competition ,Patent Term Restoration Act ,Unitary Patent System ,Dodd Frank Wall Street Reform ,Consumer Protection Act ,Registration Statement ,Chief Executive Officer ,Chief Operations Officer ,National Institute ,Cybersecurity Framework Standard ,Privacy Controls ,Senior Director ,Training Compliance ,Common Equity ,Related Stockholder Matters ,Issuer Purchases ,Financial Condition ,Capital Resources ,Administrative Expenses ,Fair Value ,Warrant Liabilities ,Years Ended December ,Operating Activities ,Investing Activities ,Financing Activities ,Income Taxes ,Dividend Yield ,Free Interest Rate ,Own Equity ,Qualitative Disclosures About Market ,Consolidated Financial ,Comprehensive Loss ,Cash Flows ,Consolidated Financial Statements ,Significant Accounting Policies ,Financial Accounting Standards Board ,Accounting Standards Codification ,Vincerx Pharma Gmbh ,Accounting Bulletin ,Ended December ,Cash Equivalents ,Development Costs ,Currency Translation ,Common Stock ,Reportable Segment Disclosures ,Income Tax Disclosures ,Vincera Pharma Common Stock ,Legacy Vincerx Pharma ,Value Measurement ,Sheet Details ,Accounting Standard Codification ,Consolidated Balance Sheet ,Employee Stock Purchase Program ,Based Compensation ,Stock Purchase Plan ,Internal Revenue ,Share Applicable ,Common Stockholders ,Jobs Act ,Internal Revenue Code ,Disagreements With Accountants ,Disclosure Controls ,Chief Financial Officer ,Internal Control ,Financial Reporting ,Integrated Framework ,Sponsoring Organizations ,Regarding Foreign Jurisdictions ,Executive Officers ,Proxy Statement ,Regulations K ,General Counsel ,Chief Legal Officer ,Sheridan Avenue ,Director Compensation ,Director Compensation Arrangements ,Certain Beneficial Owners ,Related Stockholder ,Compensation Plan ,Related Transactions ,Voting Agreement ,Director Independence ,Corporate Governance ,Certain Relationships ,Accountant Fees ,Independent Registered Public Accounting ,Extension Schema ,Extension Calculation Linkbase ,Extension Definition Linkbase ,Extension Label Linkbase ,Extension Presentation Linkbase ,Page Interactive Data File ,Financial Statement Schedules ,Principal Executive Officer ,Principal Financial Officer ,Principal Accounting Officer ,